Back to News
Market Impact: 0.18

AST SpaceMobile vs. Rocket Lab: 1 Number Separates These Space Stocks

ASTS
GAP
GETY
HRDI
NFLX
NVDA
PPLI
RKLB
Company FundamentalsCorporate Guidance & OutlookCapital Returns (Dividends / Buybacks)Investor Sentiment & Positioning

Rocket Lab generated roughly $200M revenue in a single quarter (up 60% YoY), versus AST SpaceMobile guiding to ~$150M–$200M revenue for all of 2026—meaning Rocket Lab books about 3 months of revenue in the span AST targets for 12 months. The article frames this as a maturity/risk-and-timing gap: Rocket Lab is already selling proven services with a $2B+ backlog, while AST has $1B+ in contracted commitments but is still transitioning from network buildout to commercial scale. Both companies remain unprofitable, so the comparison is positioned as a speculative risk-versus-upside decision rather than a clear fundamental “beat.”

Analysis

The market mechanism here is not “space” exposure, it’s duration versus de-risking. RKLB is increasingly trading like a scaled industrial platform with visible backlog conversion, so its multiple should be less volatile and more defensible in a risk-off tape; ASTS is still a financing-and-execution story where every quarter without clear commercialization raises the probability of dilution before the revenue curve steepens. That means the relative winner over the next 1-3 months is likely the name with better cash conversion, not the larger theoretical end-market.

Second-order, ASTS’s upside case only becomes investable if carrier usage proves that direct-to-device traffic is incremental rather than promotional. If usage is real, the company can re-rate violently because the current revenue base is too small to matter; if not, the stock is vulnerable to multiple compression even before the balance sheet is stressed. For RKLB, the key risk is a growth deceleration shock: the stock can absorb headline volatility, but not a backlog-to-revenue conversion miss or margin stall.

Consensus is over-indexing on revenue size as the wrong proxy. What matters is capital intensity per dollar of future revenue: RKLB can compound with less external funding, while ASTS likely needs operational proof fast enough to outrun the cash burn clock. The clean falsifier is simple: if ASTS shows accelerating commercial throughput without a new equity raise over the next two quarters, the bear thesis weakens materially; if RKLB’s growth or backlog conversion slips, the quality premium should compress quickly.